$ alzcure是通过分散科学（DESCI）为阿尔茨海默氏症研究的开创性区块驱动的资金

它建立在Solana的基础上，可以使社区驱动的基因疗法和神经元再生的支持。

The initiative, operating on a decentralized funding model, aims to ensure that researchers, biotech firms, and investors can collaborate smoothly in a Web3 ecosystem. By ensuring real-time financial support for high-impact research projects and streamlining the administrative burden, Alzheimer's Cure Charity Token is aiming to transform how medical research is funded and executed.

该计划以分散的资金模型运行，旨在确保研究人员，生物技术公司和投资者可以在Web3生态系统中平稳地合作。通过确保对高影响力研究项目的实时财政支持并简化行政负担，阿尔茨海默氏症的Cure Charity Charity Token的目标是改变医学研究的资金和执行方式。

With a focus on epignetic therapies and neuron regeneration, including the study of Yamanaka Factors for restoring lost neuronal function, the project is also funding research into gene therapy and regenerative medicine solutions for Alzheimer's disease and other neurodegenerative conditions.

该项目侧重于静脉疗法和神经元再生，包括研究雅马卡因恢复神经元功能丧失的因素的研究，该项目还为阿尔茨海默氏病和其他神经退行性疾病的基因疗法和再生医学解决方案提供资金。

This endeavor aligns with the broader goal of moving beyond symptom management and developing disease-modifying therapies that could fundamentally alter the course of neurodegenerative diseases like Alzheimer's.

这项工作与超越症状管理和开发疾病改良疗法的更广泛的目标相吻合，这些疗法可能从根本上改变了像阿尔茨海默氏症这样的神经退行性疾病。

The process of securing traditional research funding is often deemed slow, bureaucratic, and highly competitive, rendering access to critical resources scarce. Despite billions invested in Alzheimer's research over the years, a cure remains elusive, and most treatments concentrate on managing symptoms rather than addressing the root causes of neurodegeneration.

获得传统研究资金的过程通常被认为是缓慢，官僚和竞争激烈的，使得获得关键资源的机会很少。尽管多年来对阿尔茨海默氏症的研究进行了数十亿美元的投资，但治愈仍然难以捉摸，大多数治疗方法都集中于管理症状，而不是解决神经退行性的根本原因。

In response to these challenges, Alzheimer's Cure Charity Token is introducing a decentralized, blockchain-powered funding model that ensures direct, traceable, and instant financial support for promising research initiatives. Through smart contracts, Alzheimer's Cure Charity Token facilitates seamless transactions, reducing administrative overhead and ensuring that funding reaches researchers without unnecessary delays.

为了应对这些挑战，阿尔茨海默氏症的CURE CHARITY CHARITY TOKEN引入了一个分散的区块链供电的资金模型，可确保直接，可追溯和即时的财务支持，以实现有前途的研究计划。通过智能合约，阿尔茨海默氏症的治疗慈善机构令牌有助于无缝交易，减少行政开销，并确保资金在没有不必要的延迟的情况下到达研究人员。

One of the key areas of focus for Alzheimer's Cure Charity Token is cellular reprogramming and neuron regeneration, particularly through the study of Yamanaka Factors, a Nobel Prize-winning discovery in epigenetics that has shown potential in restoring lost neuronal function. By funding research into gene therapy, regenerative medicine, and advanced medical solutions, Alzheimer's Cure Charity Token is aiming to move beyond symptom management and toward disease-modifying therapies.

阿尔茨海默氏症治疗慈善令牌的关注点之一是细胞重编程和神经元再生，尤其是通过研究Yamanaka因素，Yamanaka因素是表观遗传学中诺贝尔奖获奖的发现，其潜力在恢复了损失的Neuronal功能方面。通过资助基因疗法，再生医学和先进的医疗解决方案的研究，阿尔茨海默氏症的治疗慈善机构令牌的目的是超越症状管理和疾病改良疗法。

Key Features of $ALZcure

$ alzcure的主要功能

* Blockchain-Powered Research Grants - Smart contracts facilitate direct and secure funding for high-impact projects.

*由区块链驱动的研究补助金 - 智能合约有助于直接和确保高影响力项目的资金。

* Decentralized Community Governance - Token holders can participate in voting and decision-making regarding fund allocation and research priorities.

*分散的社区治理 - 代币持有人可以参与有关基金分配和研究优先事项的投票和决策。

* Focus on Gene Therapy & Neurodegeneration - Supporting research into Alzheimer's, Parkinson's, Dementia, Stroke, ALS, Multiple Sclerosis (MS), Huntington's disease, and other neurodegenerative conditions.

*专注于基因治疗和神经退行性 - 支持对阿尔茨海默氏症，帕金森氏症，痴呆症，中风，ALS，多发性硬化症（MS），亨廷顿氏病和其他神经退行性疾病的研究。

* Staking and Rewards Mechanism - Holders can stake $ALZcure tokens to earn rewards while contributing to long-term research funding.

*积分和奖励机制 - 持有人可以将$ alzcure代币持有奖励，同时为长期研究资金做出贡献。

* Transparency & Speed - Blockchain-based transactions ensure efficient, real-time financial distribution with full traceability.

*透明度和速度 - 基于区块链的交易可确保具有完整可追溯性的高效实时财务分配。

The Urgent Need for Innovation in Alzheimer's Research

阿尔茨海默氏症研究的迫切需要

Alzheimer's disease currently affects over 55 million people worldwide, and this number is expected to triple by 2050. Despite substantial investments in research, progress in developing effective treatments remains slow, and most available therapies provide only temporary relief from symptoms rather than addressing the underlying causes of neurodegeneration.

阿尔茨海默氏病目前在全球范围内影响超过5500万人，预计到2050年，这一数字将在研究中进行三倍。尽管进行了大量研究，但开发有效治疗的进展仍然缓慢，而且大多数可用的疗法仅提供临时缓解症状，而不是解决神经报道的潜在原因。

Alzheimer's Cure Charity Token aims to bridge this gap by introducing a community-driven funding model that enables investors, researchers, and medical professionals to collaborate in real-time. By leveraging decentralized funding mechanisms, Alzheimer's Cure Charity Token expedites financial support for promising scientific projects, allowing them to progress more efficiently toward clinical trials and potential FDA approvals.

阿尔茨海默氏症的CURE慈善机构令牌旨在通过引入社区驱动的资金模型来弥合这一差距，该模型使投资者，研究人员和医疗专业人员能够实时合作。通过利用分散的资金机制，阿尔茨海默氏症的Cure Cure Charity代币加快了对有希望的科学项目的财政支持，从而使他们能够更有效地朝着临床试验和潜在的FDA批准方面进步。

$ALZcure Partners with YouthBio Therapeutics to Advance Alzheimer's Research

$ alzcure与Youthbio Therapeutics合作，以推进阿尔茨海默氏症的研究

Alzheimer's Cure Charity Token has partnered with YouthBio Therapeutics, a biotech firm specializing in epigenetic rejuvenation and longevity therapies, to accelerate Alzheimer's research.

阿尔茨海默氏症的CURE CHARITY TOKEN已与Foundbio Therapeutics合作，这是一家专门从事表观遗传复兴和长寿疗法的生物技术公司，以加速阿尔茨海默氏症的研究。

YouthBio has been conducting preclinical studies on age-related cognitive decline and Progeria using ARTE10 mice, showing promise in both areas. The company has also received a Rare Pediatric Disease Designation from the FDA for Progeria, making it eligible for a Priority Review Voucher (PRV)-a designation that could fast-track future treatments.

Youthbio一直在使用ARTE10小鼠对与年龄相关的认知下降和后代进行临床前研究，这在这两个地区都有希望。该公司还从FDA获得了FDA的罕见儿科疾病名称，使其有资格获得优先审查凭证（PRV） - 可以快速训练未来治疗的指定。

With plans to initiate human trials in Australia, YouthBio is currently working with local regulators and engaging with the FDA for an Investigational New Drug (IND) filing in the U.S. This collaboration aligns with Alzheimer's Cure Charity Token's mission to support cutting-edge biotech research through decentralized funding, helping to speed up the development of groundbreaking therapies for Alzheimer's and other neurodegenerative diseases.

With plans to initiate human trials in Australia, YouthBio is currently working with local regulators and engaging with the FDA for an Investigational New Drug (IND) filing in the US This collaboration aligns with Alzheimer's Cure Charity Token's mission to support cutting-edge biotech research through decentralized funding, helping to speed up the development of groundbreaking therapies for Alzheimer's and other neurodegenerative diseases.